Study Reveals Lactation-Suppressing Drug Could Reduce Breast Cancer Risk

An international research team from Spain's Cancer Research Center has discovered that cabergoline, a medication used to suppress breast milk production after childbirth, may reduce breast cancer risk by approximately half when administered at the end of lactation. The findings suggest a new preventive pathway for breast cancer, one of the most common cancers affecting women worldwide. This discovery opens potential new applications for an existing medication, offering hope for improved cancer prevention strategies. The research could have significant implications for postpartum women seeking additional protective measures against breast cancer development.